# A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants

> **NCT06133049** · — · ACTIVE_NOT_RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 2961 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Ozanimod
- **DRUG:** Select DMTs other than ozanimod
- **DRUG:** No DMTs

## Key facts

- **NCT ID:** NCT06133049
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-16
- **Primary completion:** 2031-03-31
- **Final completion:** 2031-08-31
- **Target enrollment:** 2961 (ESTIMATED)
- **Last updated:** 2023-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06133049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06133049, "A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06133049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*